Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 226.76B +11.6% |
| Revenue (ttm) | 45.81B +2.7% |
| Net Income | 10.31B -6.6% |
| EPS | 5.34 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 22.32 |
| Forward PE | 15.19 |
| Dividend | 3.70 (3.10%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 3,006,350 |
| Open | 121.00 |
| Previous Close | 119.96 |
| Day's Range | 119.24 - 122.16 |
| 52-Week Range | 97.05 - 132.68 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 125.26 (+5.0%) |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 125.26, which is an increase of 5.00% from the latest price.
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contac...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dan...
US FDA expands use of Novartis drug for chronic skin condition
The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, the Swiss drugmaker said on Wednesday.
Novartis announces FDA approval of Rhapsido for symptomatic dermographism
Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Rhapsido...
Novartis to present data from MS portfolio with 46 abstracts at MSToronto2026
Novartis (NVS) will present new data from its multiple sclerosis, MS, portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Among these is a late-breaking abstract feat...
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Novartis' experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial m...
Novartis price target lowered to $156 from $170 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novartis (NVS) to $156 from $170 and keeps an Overweight rating on the shares. The firm lowered the price…
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the pas...
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
Novartis signs mRNA deal for about $7.8 billion with China's Abogen
Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy.
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Novartis announces positive CHMP opinion for Cosentyx
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Cosentyx in po...
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmake...
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Novartis: More Pain on the Way?
The bad diagnoses just keep on coming for the Swiss drugmaker.
Novartis investors to increase scrutiny of company’s strategy, Reuters reports
Novartis (NVS) investors will be increasing their scrutiny of the company’s dealmaking strategy following setbacks to drugs acquired through mergers and acquisitions, Bhanvi Satija, Oliver Hirt and Ma...
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its...
Novartis shareholder calls for board changes, Reuters reports
A major Novartis (NVS) shareholder is calling for board changes following successive clinical setbacks and concerns over the company’s acquisition track record, arguing that stronger deal oversight an...
Major Novartis shareholder calls for board shake-up after drug trial setbacks
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial...
HSBC upgrades Novartis to Hold with negative catalysts played out
HSBC last night upgraded Novartis (NVS) to Hold from Reduce with a price target of $136, up from $123. The firm believes the company’s negative catalyst path has played out…
Novartis upgraded to Hold from Reduce at HSBC
HSBC upgraded Novartis (NVS) to Hold from Reduce with a CHF 110 price target
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen d...
Novartis price target lowered to CHF 135 from CHF 142 at Citi
Citi lowered the firm’s price target on Novartis (NVS) to CHF 135 from CHF 142 and keeps a Buy rating on the shares.